Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 4, 2014, Pages 837-844

  Esnaola, Nestor F ^a   Chaudhary, Uzair B ^b   O'Brien, Paul ^b   Garrett Mayer, Elizabeth ^b   Camp, E Ramsay ^a   Thomas, Melanie B ^b   Cole, David J ^a   Montero, Alberto J ^b   Hoffman, Brenda J ^b   Romagnuolo, Joseph ^b   Orwat, Kelly P ^a   Marshall, David T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES;

CHEMO RADIATIONS; INTENSITY MODULATED RADIATION THERAPY; LOCALLY ADVANCED PANCREATIC CANCERS; MEDIAN SURVIVAL; METHODS AND MATERIALS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURGICAL RESECTION;

CHEMORADIOTHERAPY;

CAPECITABINE; CETUXIMAB; GEMCITABINE; HEMOGLOBIN; INFUSION FLUID; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; BILIARY STENT; BLOOD TOXICITY; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DETERIORATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROLYTE DISTURBANCE; ENDOSCOPIC ECHOGRAPHY; FEMALE; FLUID THERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERNATREMIA; HYPERSENSITIVITY; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INDUCTION CHEMOTHERAPY; INFUSION RELATED REACTION; INTENSITY MODULATED RADIATION THERAPY; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; LEUKOPENIA; LOCALLY ADVANCED PANCREATIC CANCER; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE JAUNDICE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOTHERAPY PLANNING SYSTEM; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84895769716     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.12.030     Document Type: Article

References (18)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. S.F. Sener, A. Fremgen, and H.R. Menck et al. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1999 1 7
3. J.G. Fortner Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results Ann Surg 199 1984 418 425
4. P.W. Pisters, J.E. Lee, and J.N. Vauthey et al. Laparoscopy in the staging of pancreatic cancer Br J Surg 88 2001 325 337
5. R.R. White, E.K. Paulson, and K.S. Freed et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation J Gastrointest Surg 5 2001 626 633
6. R.C. Liu, and L.W. Traverso Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography Surg Endosc 19 2005 638 642
7. M. Shoup, C. Winston, and M.F. Brennan et al. Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma? J Gastrointest Surg 8 2004 1068 1071
8. R. Taylor, K.J. Opfermann, and B.D. Jones et al. Comparison of radiation treatment delivery for pancreatic cancer: Linac IMRT versus helical tomotherapy J Med Imaging Radiat Oncol 56 2012 332 337
9. C. Louvet, R. Labianca, and P. Hammel et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509 3516
10. J.R. Merchan, A. Ferrell, and J. Macintyre et al. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer Am J Clin Oncol 35 2011 446 450
11. C.H. Crane, G.R. Varadhachary, and J.S. Yordy et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression J Clin Oncol 29 2011 3037 3043
12. F. Leone, M. Gatti, and P. Massucco et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience Cancer 119 2013 277 284
13. M.P. Callery, K.J. Chang, and E.K. Fishman et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement Ann Surg Oncol 16 2009 1727 1733
14. Y.S. Chun, B.N. Milestone, and J.C. Watson et al. Defining venous involvement in borderline resectable pancreatic cancer Ann Surg Oncol 17 2010 2832 2838
15. F. Kullmann, A. Hartmann, and R. Stohr et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: Results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy Oncology 81 2001 3 8
16. M.H. Katz, J.B. Fleming, and P. Bhosale et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators Cancer 118 2012 5749 5756
17. T. Conroy, F. Desseigne, and M. Ychou et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
18. P.J. Hosein, J. Macintyre, and C. Kawamura et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma BMC Cancer 12 2012 199